<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">61287</article-id><article-id pub-id-type="doi">10.7554/eLife.61287</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-198813"><name><surname>Roelofs</surname><given-names>Pieter A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198814"><name><surname>Goh</surname><given-names>Chai Yeen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198815"><name><surname>Chua</surname><given-names>Boon Haow</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198817"><name><surname>Jarvis</surname><given-names>Matthew C</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198816"><name><surname>Stewart</surname><given-names>Teneale A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198818"><name><surname>McCann</surname><given-names>Jennifer L</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0458-1335</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198819"><name><surname>McDougle</surname><given-names>Rebecca M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198820"><name><surname>Carpenter</surname><given-names>Michael A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-194771"><name><surname>Martens</surname><given-names>John WM</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-197510"><name><surname>Span</surname><given-names>Paul N</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1930-6638</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198821"><name><surname>Kappei</surname><given-names>Dennis</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3582-2253</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-141053"><name><surname>Harris</surname><given-names>Reuben S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9034-9112</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Biochemistry</institution>, <institution>University of Minnesota</institution>, <addr-line><named-content content-type="city">Minneapolis</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Translational Medicine</institution>, <institution>National University of Singapore</institution>, <addr-line><named-content content-type="city">Singapore</named-content></addr-line>, <country>Singapore</country></aff><aff id="aff3"><institution content-type="dept">Microbiology and Immunology</institution>, <institution>University of Minnesota</institution>, <addr-line><named-content content-type="city">Minneapolis</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Biochemistry</institution>, <institution>Howard Hughes Medical Institute, University of Minnesota</institution>, <addr-line><named-content content-type="city">Minneapolis</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution>Erasmus MC Cancer Institute, Erasmus University Medical Center</institution>, <addr-line><named-content content-type="city">Rotterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff6"><institution>Radboud University Medical Center</institution>, <addr-line><named-content content-type="city">Nijmegen</named-content></addr-line>, <country>Netherlands [NL]</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-33764"><name><surname>Murphy</surname><given-names>Maureen E</given-names></name><role>Reviewing editor</role><aff><institution>The Wistar Institute</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>rsh@umn.edu</email> (RH);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>09</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e61287</elocation-id><history><date date-type="received"><day>24</day><month>07</month><year>2020</year></date><date date-type="accepted"><day>25</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Roelofs et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Roelofs et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-61287-v1.pdf"/><abstract><p>APOBEC3B (A3B)-catalyzed DNA cytosine deamination contributes to the overall mutational landscape in breast cancer. Molecular mechanisms responsible for <italic>A3B</italic> upregulation in cancer are poorly understood. Here, we show that a single E2F cis-element mediates repression in normal cells and that expression is activated by its mutational disruption in a reporter construct or the endogenous <italic>A3B</italic> gene. The same E2F site is required for <italic>A3B</italic> induction by polyomavirus T antigen indicating a shared molecular mechanism. Proteomic and biochemical experiments demonstrate binding of wildtype but not mutant E2F promoters by repressive PRC1.6/E2F6 and DREAM/E2F4 complexes. Knockdown and overexpression studies confirm involvement of these repressive complexes in regulating A3B expression. Altogether, these studies demonstrate that <italic>A3B</italic> expression is suppressed in normal cells by repressive E2F complexes and that viral or mutational disruption of this regulatory network triggers overexpression in breast cancer and provides fuel for tumor evolution.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P01-CA234228</award-id><principal-award-recipient><name><surname>Harris</surname><given-names>Reuben S</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004622</institution-id><institution>KWF Kankerbestrijding</institution></institution-wrap></funding-source><award-id>KWF10270</award-id><principal-award-recipient><name><surname>Martens</surname><given-names>John WM</given-names></name><name><surname>Span</surname><given-names>Paul N</given-names></name><name><surname>Harris</surname><given-names>Reuben S</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001381</institution-id><institution>National Research Foundation Singapore</institution></institution-wrap></funding-source><award-id>NMRC/OFYIRG/055/2017</award-id><principal-award-recipient><name><surname>Kappei</surname><given-names>Dennis</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Reuben S Harris, RSH is a co-founder, shareholder, and consultant of ApoGen Biotechnologies Inc..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Raw mass spectrometry data will be accessible through the ProteomeXchange Consortium via the PRIDE (Vizcaino et al., 2016) partner repository with the dataset identifier PXD020473. Additional data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-61287-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>